Atonarp, a manufacturer of molecular sensing and diagnostics products for the healthcare, pharma, and semiconductor industries with operations in Japan, India, and the United States, raised $50m in Series D financing.
The round was led by WRVI Capital with participation from Furukawa Electric, Japan Post Investment, Boscolo Intervest, ATI Korea, and Banner Industries. In conjunction with the funding, WRVI Capital Founding Partner Michael Marks joined Atonarp’s Board.
The company, which has raised $111M in funding to date, intends to use the funds to expand its operations and expedite the development and commercialization of its molecular diagnostics products.
Founded in 2010 by president and CEO, CTO, and founder Prakash Murthy, and also led by newly appointed COO Shaun Holt, Atonarp is a molecular diagnostics company innovating how sensing and diagnostics devices are applied to generate real-time actionable data and achieve improved outcomes in healthcare and industrial semiconductor processes.
The company uses its proprietary spectroscopic technology to detect, analyze, and quantify molecular information. Its suite of molecular diagnostics products include the ATON-360™, an end-to-end platform that enables lab-quality results using optical sensors.